Filtern
Volltext vorhanden
- ja (20)
Gehört zur Bibliographie
- ja (20)
Dokumenttyp
Sprache
- Englisch (20)
Schlagworte
- DNA methylation (2)
- EEG (2)
- IAPS (2)
- MDD (2)
- MEG (2)
- antidepressants (2)
- anxiety (2)
- anxiety disorders (2)
- dorsolateral prefrontal cortex (2)
- fear conditioning (2)
- fear generalization (2)
- life events (2)
- major depression (2)
- panic disorder (2)
- parietal hypoactivation (2)
- regulatory T cells (2)
- temporoparietal junction (2)
- ADHD (1)
- Alzheimers disease (1)
- Big Five (1)
- CAPS (1)
- CDH13 (1)
- COMT VAL(158)MET polymorphism (1)
- COVID-19 (1)
- Dorsolateral prefrontal cortex (1)
- Human behaviour (1)
- Hurst Exponent (1)
- Medizin (1)
- PTSD (1)
- Personalized medicine (1)
- Prognostic markers (1)
- Psychiatric disorders (1)
- VAL66MET polymorphism (1)
- VBM (1)
- acid sphingomyelinase (1)
- acoustic startle (1)
- adversity (1)
- aging brain (1)
- agreeableness (1)
- allostatic load (1)
- anxious depression (1)
- biomarker (1)
- bipolar disorder (1)
- brain (1)
- caffeine-induced anxiety (1)
- childhood maltreatment (1)
- cholinergic neurons (1)
- classical conditioning (1)
- community sample (1)
- coping style (1)
- dentate gyrus (1)
- depressive disorder (1)
- development (1)
- discrimination training (1)
- epigenetics (1)
- executive functions (1)
- exposure therapy (1)
- extinction (1)
- fMRI (1)
- fear memory consolidation (1)
- fear-potentiated startle (1)
- fear-relevant training (1)
- feedback (1)
- frontal cortex (1)
- genetics (1)
- genome-wide association (1)
- hippocampal neurogenesis (1)
- impulse control disorders (1)
- inflammation (1)
- inflammatory cytokines (1)
- inflammatory diseases (1)
- intensified treatment (1)
- interleukin 6 (1)
- major depressive disorder (1)
- maturation (1)
- messenger RNA (1)
- mismatch (1)
- monoamine oxidase A (1)
- mood disorder (1)
- negative affect (1)
- nervour system (1)
- neurite outgrowth (1)
- neurodevelopment (1)
- neuroprotection (1)
- neurothrophic factor (1)
- neurotrophic factor gene (1)
- nucleus accumbens (1)
- pharmacotherapy (1)
- polygenic risk score (1)
- posttraumatic-stress-disorder (1)
- prepulse inhibition (1)
- public health (1)
- randomized controlled trial (1)
- safety behavior (1)
- sequence variations (1)
- serotonin transporter gene (1)
- skin conductance (1)
- social cognitive (1)
- sphingolipids (1)
- stressful life events (1)
- survey (1)
- telomere length (1)
- therapy response (1)
- transcranial direct current stimulation (1)
- treatment guidelines (1)
- treatment response (1)
- voxel-based morphometry (1)
- working memory (1)
Institut
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (19)
- Institut für Psychologie (9)
- Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie (5)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (2)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (1)
- Institut für Humangenetik (1)
- Institut für Organische Chemie (1)
- Institut für Virologie und Immunbiologie (1)
- Kinderklinik und Poliklinik (1)
- Neurologische Klinik und Poliklinik (1)
Sonstige beteiligte Institutionen
Anxious depression represents a subtype of major depressive disorder and is associated with increased suicidality, severity, chronicity and lower treatment response. Only a few studies have investigated the differences between anxious depressed (aMDD) and non-anxious depressed (naMDD) patients regarding treatment dosage, serum-concentration and drug-specific treatment response. In our naturalistic and prospective study, we investigated whether the effectiveness of therapy including antidepressants (SSRI, SNRI, NaSSA, tricyclics and combinations) in aMDD patients differs significantly from that in naMDD patients. In a sample of 346 patients, we calculated the anxiety somatization factor (ASF) and defined treatment response as a reduction (≥50%) in the Hamilton Depression Rating Scale (HDRS)-21 score after 7 weeks of pharmacological treatment. We did not observe an association between therapy response and the baseline ASF-scores, or differences in therapy outcomes between aMDD and naMDD patients. However, non-responders had higher ASF-scores, and at week 7 aMDD patients displayed a worse therapy outcome than naMDD patients. In subgroup analyses for different antidepressant drugs, venlafaxine-treated aMDD patients showed a significantly worse outcome at week 7. Future prospective, randomized-controlled studies should address the question of a worse therapy outcome in aMDD patients for different psychopharmaceuticals individually.